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Abstract: Evidence supporting the impact of therapeutic zinc supplementation on the 
duration and severity of diarrhea among children under five is largely derived from studies 
conducted in South Asia. China experiences a substantial portion of the global burden of 
diarrhea, but the impact of zinc treatment among children under five has not been well 
documented by previously published systematic reviews on the topic. We therefore 
conducted a systematic literature review, which included an exhaustive search of the 
Chinese literature, in an effort to update previously published estimates of the effect of 
therapeutic zinc. We conducted systematic literature searches in various databases, 
including the China National Knowledge Infrastructure (CNKI), and abstracted relevant data 
from studies meeting our inclusion and exclusion criteria. We used STATA 12.0 to pool 
select outcomes and to generate estimates of percentage difference and relative risk 
comparing outcomes between zinc and control groups. We identified 89 Chinese and  
15 non-Chinese studies for the review, including studies in 10 countries from all WHO 
geographic regions, and analyzed a total of 18,822 diarrhea cases (9469 zinc and  
9353 control). None of the included Chinese studies had previously been included in 
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published pooled effect estimates. Chinese and non-Chinese studies reported the effect of 
therapeutic zinc supplementation on decreased episode duration, stool output, stool 
frequency, hospitalization duration and proportion of episodes lasting beyond three and 
seven days. Pooling Chinese and non-Chinese studies yielded an overall 26% (95% CI: 
20%−32%) reduction in the estimated relative risk of diarrhea lasting beyond three days 
among zinc-treated children. Studies conducted in and outside China report reductions in 
morbidity as a result of oral therapeutic zinc supplementation for acute diarrhea among 
children under five years of age. The WHO recommendation for zinc treatment of diarrhea 
episodes should be supported in all low- and middle-income countries. 
Keywords: zinc; children; global health; China 
 
1. Introduction 
In response to mounting evidence supporting the efficacy and effectiveness of therapeutic zinc 
supplementation for diarrhea among children under five years of age, the World Health Organization 
(WHO) and the United Nation’s Children Fund (UNICEF) issued a global recommendation in 2004, 
which advised zinc supplementation in addition to oral rehydration solution (ORS) for the treatment of 
all diarrhea episodes among children <5 years of age [1,2]. Systematic reviews have quantified the 
association between therapeutic zinc supplementation and a reduction in the duration and severity of 
childhood diarrhea episodes in low- and middle-income countries (LMICs) [1,3,4]. Many of the studies 
contributing to this body of evidence were conducted in South Asia [5–7], but literature stemming from 
East Asia has not been included in past reviews. In 2011, Zhang published a systematic review which 
identified 11 Chinese studies assessing zinc treatment for diarrhea and signified the need to update 
previous meta-analyses with literature published in languages other than English [8]. 
We sought to conduct an extensive search for studies of oral therapeutic zinc supplementation 
published in Chinese and any other language. We also aimed to combine evidence across regions in 
order to generate global estimates of the effect of oral therapeutic zinc supplementation on selected 
morbidity and mortality outcomes among children under five years of age. 
2. Methods 
We conducted a systematic literature search for studies published in any language between 1980 and 
November 2012 using the MeSH search terms “zinc” and “diarrhea” limited to “humans” in the 
following databases: Biosis, Cumulative Index to Nursing and Allied Health (CINAHL), Cochrane 
Central Register of Controlled Trials (CENTRAL), Embase, the WHO International Clinical Trials 
Registry Platform (ICTRP), Global Health, Latin American and Caribbean Health Sciences Literature 
(LILACS), PubMed, Scopus, Web of Science, IndMed, Egyptian Universities Library Consortium, 
Index Medicus for the Eastern Mediterranean Region (IMEMR), China National Knowledge 
Infrastructure (CNKI), WanFang, and Chinese BioMedical (CBM) database. 
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Titles and abstracts were reviewed by two independent reviewers, and complete manuscripts were 
obtained for further review of pertinent studies. Discrepancies were resolved in consultation with a third 
reviewer. We restricted inclusion to individually randomized controlled trials (RCTs) of children under 
five years of age with acute diarrhea, including dysentery, where diarrhea was defined as the passage of 
at least three loose or watery stools in a 24-h period. We excluded cluster RCTs, studies that exclusively 
enrolled a particular subgroup of children (e.g., HIV-infected children; preterm infants), and studies of 
persistent diarrhea. We included RCTs assessing oral zinc supplementation of any zinc salt in 
comparison to a control group receiving placebo supplement. For studies conducted in China, where 
placebo supplements may not have been readily available, we included trials in which cases received the 
same supportive therapy regardless of zinc allocation. For all studies, administration of minerals 
(excluding iron), vitamins, and supporting therapy beyond zinc were only considered acceptable if these 
were received by both the intervention and control groups. Studies that used supplements that included 
iron, zinc-fortified ORS, or zinc-fortified foods were excluded. 
Included studies were reviewed for the following outcomes: diarrhea duration; the proportion of 
diarrhea episodes lasting >3 and >7 days; duration of hospitalization; duration of fever; duration of 
vomiting; proportion of cases vomiting; stool frequency (number per day); stool output (mL); and death 
from diarrhea or any cause. Two independent reviewers entered data into structured tables, and 
discrepancies were resolved in consultation with a third reviewer. 
We conducted independent analyses for studies assessing diarrhea due to unspecified causes and 
those assessing specific pathogens (e.g., rotavirus) that were laboratory confirmed prior to enrollment. 
All data analyses were conducted in STATA 12.0 [9]. We fit Poisson and logistic regression models to 
continuous and binary outcomes, respectively, weighting all outcomes by sample size. These models 
generated pooled estimates and 95% confidence intervals lower bound by zero for all outcomes and 
upper bound by one for proportions. 
For continuous outcomes, we calculated the overall percentage difference between the pooled 
estimates for the zinc and control groups. For binary outcomes, we calculated estimates of relative risk 
(RR) with placebo as the reference group and conducted random effects meta-analyses to combine RRs 
across studies [9]. 
We conducted hypothesis testing to assess the equivalence of pooled outcomes and of effect estimates 
by placebo and non-placebo controlled trials. To compare effect estimates, we tested the difference of 
mean percentage differences for continuous outcomes and the ratio of relative risks (RRR) for binary 
outcomes [10]. We subsequently pooled placebo and non-placebo controlled trials for outcomes with no 
statistically significant difference in effect size. 
We assessed the association between the dose of oral zinc supplement and diarrhea duration by 
regressing the mean percentage difference in diarrhea duration comparing the zinc and control groups 
onto a categorical variable which indicated whether zinc dose was lower than, equal to, or greater than 
the WHO recommendation. 
During the course of our analyses, we identified a zinc product called Licorzinc that appeared to be 
unique to China. To determine whether outcomes for Chinese studies were generalizable comparing 
Licorzinc to other better established zinc products, we conducted hypothesis testing to assess the 
equivalence of the mean percentage difference in episode duration between zinc and placebo. We also 
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calculated the RRR to compare the RR of episodes lasting >3 days between studies using Licorzinc and 
other zinc products. 
We plotted funnel plots to assess our primary outcomes for publication bias. We also employed the 
Child Health Epidemiology Reference Group (CHERG) grading system to assess the quality of evidence 
for each outcome on a four-point scale (“high”, “moderate”, “low”, “very low”) [11]. 
3. Results 
The systematic literature search of the non-Chinese databases uncovered 4038 titles, and 15 were 
included after subsequent review of abstracts and full manuscripts for inclusion and exclusion criteria 
(Figure 1) [5–7,12–23]. Of the included studies, 13 were conducted in a hospital setting and two 
assessed episodes occurring in the community. Included studies were conducted in sites located within  
10 countries: India (n = 6); Bangladesh (n = 5); Nepal (n = 1); Turkey (n = 1); Brazil (n = 1); Pakistan  
(n = 1); Ethiopia (n = 1); Yemen (n = 1); and Poland (n = 1). These studies enrolled a total of  
3271 zinc-allocated and 3314 placebo-allocated diarrhea cases. The systematic literature search for 
Chinese studies resulted in 1520 titles, of which 89 were included (Figure 1) [24–112]. All included 
studies were conducted in a hospital setting, and 33 studies focused on diarrhea attributable to laboratory 
confirmed rotavirus. None of the included studies identified through the Chinese database were 
placebo-controlled; for Chinese studies, zinc and control groups received a range of supportive 
treatments, including fluid infusion, probiotics and antivirals. The total enrolment of included Chinese 
studies was 6198 zinc group and 6039 control group diarrhea cases. Table 1 describes the trial setting, 
sample size, and zinc intervention for all included studies. 
Figure 1. Results of systematic literature search and review. 
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Table 1. Characteristics of included studies. 
Author 
[Reference] 
Year 
Published 
Country 
Trial 
Setting 
Specific 
Causative 
Organisms
Age Group 
(months) 
Sample Size 
Zinc Salt 
Tablet 
or 
Syrup 
Daily Zinc Dose 
Length of 
Supplementation 
(days) 
Zinc 
Group
Control 
Group 
Al Sonboli [17] 2003 Brazil Hospital Unknown 3–60 37 37 Not Listed Tablet 
3–5 mos: 22.5 mg 
6–60 mos: 45 mg 
5 
Bahl [7] 2002 India Community Unknown 6–35 404 401 Zinc Gluconate Syrup 
6–11 mos: 15 mg 
12–35 mos: 30 mg 
14 
Brooks [16] 2005 Bangladesh Hospital Unknown 1–6 91 93 Zinc Acetate Syrup 20 mg Duration of episode 
Brooks [16] 2005 Bangladesh Hospital Unknown 1–6 91 93 Zinc Acetate Syrup 5 mg Duration of episode 
Dutta [23] 2011 India Hospital Unknown 6–24 44 41 Not Listed Syrup 40 mg 14 
Elnemr [21] 2007 Yemen Hospital Unknown 3–24 88 92 Zinc Acetate Syrup 20 mg 14 
Faruque [12] 1999 Bangladesh Hospital Unknown 6–24 343 341 Zinc Acetate Syrup 14.2 mg 15 
Fischer Walker [19] 2006 Pakistan Hospital Unknown 1–5 281 279 Zinc Sulfate Tablet 10 mg 14 
Fischer Walker [19] 2006 India Hospital Unknown 1–5 186 187 Zinc Sulfate Tablet 10 mg 14 
Fischer Walker [19] 2006 Ethiopia Hospital Unknown 1–5 87 90 Zinc Sulfate Tablet 10 mg 14 
Larson [18] 2005 Bangladesh Hospital Unknown 3–59 267 266 Zinc Sulfate Tablet 20 mg 10 
Patel [20] 2009 India Hospital Unknown 6–59 264 271 Zinc Sulfate Syrup 20 mg 14 
Patro [22] 2010 Poland Hospital Unknown 3–48 81 79 Zinc Sulfate Syrup 
3–5 mos: 10 mg 
6–48 mos: 20 mg 
10 
Polat [15] 2003 Turkey Hospital Unknown 2–29 52 54 Zinc Sulfate Syrup 20 mg 10 
Roy [13] 1999 Bangladesh Hospital Unknown 3–24 32 35 Zinc Acetate Syrup 20 mg 14 
Sachdev [5] 1988 India Hospital Unknown 6–18 25 25 Zinc Sulfate Tablet 40 mg Not Listed 
Sazawal [6] 1995 India Hospital Unknown 6–35 456 481 Zinc Gluconate Syrup 20 mg Not Listed 
Strand [14] 2002 Nepal Community Unknown 6–35 442 449 Not Listed Syrup 
6–11 mos: 15 mg 
12–35 mos: 30 mg 
From enrolment 
until 7 days after 
episode subsided 
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Table 1. Cont. 
Zhao [24] 2011 China Hospital Unknown 4–36 40 40 Licorzinc Tablet 
4–5 mos: 10.8 mg 
6–12 mos: 14.4 mg 
13–36 mos: 21.6 mg 
Not Listed 
Zhang [25] 2009 China Hospital Rotavirus 6–24 60 60 Zinc Gluconate 
Not 
Listed 
20 mg Duration of episode 
Lin [26] 2010 China Hospital Rotavirus 1.5–36 58 58 Zinc Gluconate Syrup 
1.5–5 mos: 10 mg 
6–36 mos: 20 mg 
Duration of episode 
Zhou [27] 2010 China Hospital Rotavirus 6–24 42 40 Zinc Gluconate 
Not 
Listed 
20 mg 14 
Yang [28] 2011 China Hospital Unknown 3–36 42 40 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Liu [29] 2010 China Hospital Unknown 5–18 40 40 Zinc Gluconate 
Not 
Listed 
5 mos: 10 mg 
6–18 mos: 20 mg 
10–14 
Chen [30] 2006 China Hospital Rotavirus 0–24 30 30 Zinc gluconate 
Not 
Listed 
10 mg Not Listed 
Liu [31] 2011 China Hospital Unknown 6.8–22 90 90 Zinc Gluconate Tablet 20 mg Not Listed 
Liu [32] 2009 China Hospital Unknown 6–36 112 108 Zinc Gluconate Tablet 20 mg 10 
Fu [33] 2010 China Hospital Rotavirus 2–24 98 102 Zinc Gluconate Syrup 5 mg Not Listed 
Zhou [34] 2008 China Hospital Unknown 2–48 40 40 Licorzinc 
Not 
Listed 
2–5 mos: 7.5 mg 
6–12 mos: 11.25 mg
13–48 mos: 18.75 mg
10–14 
Chen [35] 2008 China Hospital Rotavirus 4–48 60 60 Licorzinc 
Not 
Listed 
4–5 mos: 7.2 mg 
6–48 mos: 10.8 mg 
Not Listed 
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Table 1. Cont. 
Guan [36] 2012 China Hospital Rotavirus 1.5–45.6 45 45 Licorzinc  
Not 
Listed 
1.5–5 mos: 7.5 mg 
6–11 mos: 11.25 mg
12–45.6 mos:  
18.75 mg 
10–14 
Wu [37] 2010 China Hospital Rotavirus 4–13 46 46 Licorzinc 
Not 
Listed 
4–5 mos: 10 mg 
6–13 mos: 20 mg 
Not Listed 
Zhou [38] 2010 China Hospital Unknown 6–24 65 60 Licorzinc Tablet 20 mg Not Listed 
Luo [39] 2009 China Hospital rotavirus 6–36 55 50 Licorzinc Tablet 18.75 mg Not Listed 
Zhang [40] 2010 China Hospital Unknown 5–48 50 50 Licorzinc 
Not 
Listed 
Not Listed * Not Listed 
Ju [41] 2007 China Hospital Unknown 6–36 40 38 Licorzinc Tablet 
6–12 mos: 11–25 mg
13–36 mos: 15 mg 
Not Listed 
Wang [42] 2012 China Hospital Unknown 6–36 30 30 Licorzinc Tablet Not Listed * 3 
Hong [43] 2009 China Hospital Rotavirus 3–60 140 120 Zinc Sulfate Syrup 
3–11 mos: 20 mg 
12–36 mos: 30 mg 
37–60 mos: 40 mg 
Not Listed 
Lin [44] 1994 China Hospital Unknown 0.5–24 46 58 Zinc Sulfate Syrup 10–14 mg/kg * Not Listed 
Yan [45] 2011 China Hospital Unknown 5–36 70 50 Zinc Sulfate Syrup 
5 mos: 50 mg 
6–36 mos: 100 mg 
Not Listed 
He [46] 1997 China Hospital Unknown 6–36 52 58 Zinc Gluconate 
Not 
Listed 
20 mg Not Listed 
Wei [47] 2011 China Hospital Unknown 3–36 44 42 Zinc Gluconate Syrup 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Yang [48] 2012 China Hospital Unknown 0–36 80 80 Zinc Gluconate Tablet 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
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Table 1. Cont. 
Pu [49] 2010 China Hospital Rotavirus 0–24 38 34 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
Not Listed 
Zhang [50] 2011 China Hospital Rotavirus 3–36 53 53 Zinc Gluconate 
Not 
Listed 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
Sun [51] 2008 China Hospital Unknown 1.5–36 45 45 Zinc Gluconate Syrup 
1.5–5 mos: 10 mg 
6–36 mos: 20 mg 
Not Listed 
Zhang [52] 2011 China Hospital Unknown 3–36 90 90 Zinc Gluconate Syrup 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
Not Listed 
Lin [53] 2010 China Hospital Rotavirus 6–54 28 20 Zinc Gluconate Tablet 6–54 mos: 20 mg 14 
Liu [54] 2009 China Hospital Unknown 3–36 95 91 Zinc Gluconate 
Not 
Listed 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Qiao [55] 2011 China Hospital Unknown 6–36 73 72 Zinc Gluconate Tablet 6–36 mos: 20 mg 14 
Zhang [56] 2007 China Hospital Unknown 0–24 85 90 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
10 
Zhao [57] 2012 China Hospital Unknown 0–24 70 70 Zinc Gluconate Syrup 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
10–14 
Cai [58] 2011 China Hospital Unknown 0–24 88 84 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
14 
Zhang [59] 2012 China Hospital Rotavirus 6–17 120 120 Zinc Gluconate Tablet 20 mg 10–14 
Qiao [60] 2012 China Hospital Unknown 0–24 85 85 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
10 
Zhong [61] 2012 China Hospital Rotavirus 3–48 50 50 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–48 mos: 20 mg 
10 
Wang [62] 2011 China Hospital Rotavirus 0–24 60 60 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
10 
Yang [63] 2008 China Hospital Rotavirus 0–36 164 168 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
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Table 1. Cont. 
Zhao [64] 2012 China Hospital Rotavirus 6–36 60 60 Zinc Gluconate Syrup 35 mg 10 
Ma [65] 2012 China Hospital Rotavirus 4–42 41 41 Zinc Gluconate 
Not 
Listed 
20 mg Not Listed 
Chen [66] 2012 China Hospital Rotavirus 0–36 93 93 Zinc Gluconate 
Not 
Listed 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
Hu [67] 2009 China Hospital Rotavirus 4–36 60 60 Zinc Gluconate Tablet 
4–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
Yuan [68] 2011 China Hospital Unknown 1–36 100 100 Zinc Gluconate Tablet 
1–12 mos: 70 mg 
13–36 mos: 140 mg 
14 
Tan [69] 2011 China Hospital Unknown 3-36 50 35 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Liu [70] 2010 China Hospital Unknown 0–36 89 77 Zinc Gluconate Syrup 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
Hu [71] 2011 China Hospital Unknown 3–60 108 100 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–60 mos: 20 mg 
14 
Li [72] 2008 China Hospital Unknown 6–36 40 38 Zinc Gluconate Tablet 
6–12 mos: 7.5 mg 
13–36 mos: 15 mg 
3 
Gao [73] 2012 China Hospital Unknown 3–36 74 74 Zinc Gluconate 
Not 
Listed 
3–5 mos: 10 mg 
6–36 mos: 20 mg 
14 
Wu [74] 2011 China Hospital Unknown 3–60 20 20 Zinc Sulfate Syrup 10 mg 10 
Wu [74] 2011 China Hospital Unknown 3–60 20 20 Zinc Sulfate 
Not 
Listed 
10 mg 10 
Liu [75] 2011 China Hospital Unknown 3–60 54 53 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–60 mos: 20 mg 
3–5 
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Table 1. Cont. 
Chen [76] 2010 China Hospital Unknown 5–36 42 20 Zinc Gluconate 
Not 
Listed 
5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Ma [77] 2012 China Hospital Unknown 2–36 63 63 Zinc Gluconate 
Not 
Listed 
2–5 mos: 70 mg 
6–36 mos: 140 mg 
10–14 
Lu [78] 2012 China Hospital Unknown 6–18 120 140 Zinc Gluconate 
Not 
Listed 
140 mg 10–14 
Ma [79] 2012 China Hospital Unknown 6–36 58 52 Zinc Gluconate Syrup 6–36 mos: 20 mg 10 
Ao [80] 2012 China Hospital Rotavirus 0–24 87 80 Zinc Gluconate Syrup 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
Not Listed 
Gu [81] 2011 China Hospital Unknown 3–60 56 60 Zinc Gluconate Syrup 
3–5 mos: 10 mg 
6–60 mos: 20 mg 
10 
Wen [82] 2006 China Hospital Unknown 0–24 30 29 Zinc Gluconate 
Not 
Listed 
20 mg 10–14 
Wang [83] 2011 China Hospital Unknown 3–36 60 60 Licorzinc 
Not 
Listed 
10–20 mg * Duration of episode 
Liu [84] 2012 China Hospital Rotavirus 8–30 90 90 Licorzinc 
Not 
Listed 
8–30 mos: 20 mg Not Listed 
Liu [85] 2012 China Hospital Unknown 3–60 100 100 Licorzinc Tablet 
3–5 mos: 10 mg 
6–60 mos: 20 mg 
Not Listed 
Tong [86] 2011 China Hospital Unknown 2–36 98 98 Licorzinc 
Not 
Listed 
2–5 mos: 10 mg 
6–36 mos: 20 mg 
Not Listed 
Qiu [87] 2010 China Hospital Rotavirus 1–24 53 52 Licorzinc Tablet 
1–5 mos: 10 mg 
6–24 mos: 20 mg 
14 
Kong [88] 2011 China Hospital Unknown 3–30 35 35 Zinc Gluconate Tablet 
3–5 mos: 10 mg 
6–11 mos: 15 mg 
12–30 mos: 20 mg 
14 
He [89] 2007 China Hospital Rotavirus 5–22 60 63 Zinc Gluconate 
Not 
Listed 
20 mg Not Listed 
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Table 1. Cont. 
Kang [90] 2010 China Hospital Rotavirus 6–36 92 80 Zinc Gluconate Tablet 20 mg 14 
Su [91] 2012 China Hospital Rotavirus 6–36 97 97 Zinc Gluconate 
Not 
Listed 
20 mg Not Listed 
Huang [92] 2010 China Hospital Rotavirus 2–36 100 100 Not Listed Tablet 
2–5 mos: 10 mg 
6–36 mos: 20 mg 
Not Listed 
Zhang [93] 2006 China Hospital Unknown 0–36 83 63 Licorzinc Syrup 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Wang [94] 2012 China Hospital Unknown 4–30 60 60 Zinc Gluconate Syrup 10 mg Not Listed 
Lin [95] 2008 China Hospital Unknown 0.5–34 60 60 Zinc Gluconate Tablet 
0.5–5 mos: 140 mg 
6–34 mos: 280 mg 
10–14 
Yan [96] 2011 China Hospital Unknown 6–60 57 57 Zinc Gluconate Tablet 20 mg 10 
Yu [97] 2012 China Hospital Unknown 0–36 40 40 Zinc Gluconate Tablet 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10–14 
Zhang [98] 2011 China Hospital Rotavirus 4–36 128 128 Zinc Gluconate Syrup 
4–5 mos: 10 mg 
6–36 mos: 20 mg 
14 
Xu [99] 2010 China Hospital Rotavirus 2–36 84 83 Zinc Gluconate 
Not 
Listed 
2–5 mos: 10 mg 
6–36 mos: 20 mg 
14 
Tan [100] 2010 China Hospital Unknown 3.5–60 55 55 Zinc Gluconate Syrup 
3.5–5 mos: 10 mg 
6–60 mos: 20 mg 
10–14 
Shen [101] 2012 China Hospital Rotavirus 2.5–40 46 42 Zinc Gluconate 
Not 
Listed 
2.5–5 mos: 10 mg 
6–40 mos: 20 mg 
Duration of episode 
Wang [102] 2010 China Hospital Unknown 6–48 52 51 Zinc Gluconate Tablet 20 mg Not Listed 
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Table 1. Cont. 
Chen [103] 2011 China Hospital Unknown 1–36 50 50 Zinc Gluconate Tablet 
1–5 mos: 5 mg 
6–36 mos: 10 mg 
Not Listed 
Meng [104] 2012 China Hospital Unknown 0–24 90 90 Zinc Gluconate Tablet 
0–5 mos: 2.5 mg 
6–12 mos: 5 mg 
13–24 mos: 10 mg 
Not Listed 
Zhong [105] 2010 China Hospital Unknown 1–24 60 60 Zinc Gluconate Tablet 
1–5 mos: 2.5 mg 
6–12 mos: 5 mg 
13–24 mos: 7.5 mg 
5–7 
Xie [106] 2010 China Hospital Rotavirus 6–36 128 124 Zinc Gluconate Tablet 20 mg Not Listed 
Fan [107] 2012 China Hospital Unknown 0–36 163 121 Not Listed 
Not 
Listed 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
10 
Zhou [108] 2012 China Hospital Rotavirus 6–24 75 75 Zinc Gluconate Syrup 20 mg 10–14 
Zhao [109] 2008 China Hospital Unknown 0–36 44 43 Zinc Gluconate Tablet 
0–5 mos: 10 mg 
6–24 mos: 20 mg 
Not Listed 
Wan [110] 2006 China Hospital Unknown 6–36 26 24 Not Listed 
Not 
Listed 
Not Listed Not Listed 
Yang [111] 2012 China Hospital Unknown 6–60 60 60 Not Listed 
Not 
Listed 
20 mg Not Listed 
Luo [112] 2012 China Hospital Unknown 0–36 168 196 Not Listed 
Not 
Listed 
0–5 mos: 10 mg 
6–36 mos: 20 mg 
Not Listed 
* Study not included in dose analyses. 
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The results of the studies identified through non-Chinese databases are summarized in Tables 2 and 3. 
Acute episodes were 4% (95% CI: 1%–8%) shorter in duration among children treated with zinc 
compared to those receiving placebo (Table 2). Among children hospitalized for diarrhea, the duration 
of hospitalization was reduced by 37% (95% CI: 21%–53%) comparing the zinc and control groups 
(Table 2). Stool frequency was decreased by 6% (95% CI: 2%–10%) among zinc-treated children. 
Zinc-treated children had a reduced relative risk (RR) of acute diarrhea lasting beyond three and seven 
days and an increased risk of vomiting (RR: 1.83; 95% CI: 1.40–2.39) (Table 3). 
Table 2. Pooled means of select outcomes for non-Chinese studies. 
Outcome 
Study 
Sites 1 
Pooled Mean 
(95% CI) 2 
Percent Difference 3 
N Zinc Group Control Group (%) 
Duration of  
Episode (days) 
13 3.51 (3.43–3.60) 3.67 (3.59–3.76) −4.4 (−7.8, −1.0) 
Duration of 
Hospitalization (days) 
1 2.00 (1.99–2.01) 3.17 (2.38–3.96) −36.9 (−52.6, −21.2) 
Stool Output (mL) 2 391.2 (388.5–393.8) 388.8 (386.2–391.5) 0.6 (−0.3, 1.6) 
Stool Frequency 
(Number per day) 
6 5.04 (4.88–5.19) 5.36 (5.20–5.52) −6.0 (−9.9, −2.0) 
1 Individual studies may contribute more than one study site (N) to each estimate; 2 Estimates for ≥2 study sites 
generated by Poisson regression model weighted by sample size; 3 Percent difference calculated by:  
100 × ((Pooled Zinc Estimate − Pooled Control Estimate)/Pooled Control Estimate); 95% CI calculated by: 
Percent Difference ± 1.96 × {|(meanzinc/meancontrol)| × sqrt[(std errorzinc)2/(meanzinc)2 + (std errorcontrol)2/ 
(meancontrol)2]} × 100. 
Table 3. Pooled relative risk of select outcomes for non-Chinese studies. 
Outcome 
Study 
Sites 1 
Pooled Estimate  
Percentage (95% CI) 2 
Pooled Relative Risk 3 
N Zinc Group Control Group RR (95% CI) 
Episodes > 3 days (%) 3 29.7 (26.7–32.7) 39.5 (36.3–42.7) 0.78 (0.67–0.90) 
Episodes > 7 days (%) 6 10.3 (8.9–11.7) 14.9 (13.2–16.5) 0.74 (0.55–0.99) 
Vomiting (%) 3 18.8 (16.0–21.6) 9.4 (7.3–11.4) 1.83 (1.40–2.39) 
1 Individual studies may contribute more than one study site (N) to each estimate; 2 Estimates for ≥2 study sites 
generated by logistic regression model weighted by sample size; 3 Estimates for ≥2 studies generated by 
random effects meta-analysis. 
Outcomes pooled across studies conducted in China showed reductions in the duration of diarrhea, 
hospitalization, fever, vomiting, stool output and stool frequency among zinc-treated children with acute 
diarrhea attributable to rotavirus and to non-specific causes (Table 4). The reduction in the duration of 
diarrhea was 37% (95% CI: 35%–39%) among non-specific episodes and 31% (95% CI: 29%–34%) 
among rotavirus episodes (Table 4). The RR of diarrhea lasting beyond three days was reduced among 
zinc-treated patients with non-specific (RR: 0.73; 95% CI: 0.66–0.79) and rotavirus (RR: 0.70; 95% CI: 
0.63–0.78) diarrhea (Table 5; Figures 2 and 3). 
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Table 4. Pooled means of select outcomes for Chinese studies. 
Outcome 
Specific 
Causative 
Pathogens 
Study 
Sites 1
Pooled Mean  
(95% CI) 2 
Percent Difference 3
N Zinc Group Control Group (%) 
Duration of  
Episode (days) 
Unknown 40 2.96 (2.90–3.03) 4.68 (4.60–4.77) −36.8 (−38.7, −34.8) 
Rotavirus 24 3.45 (3.36–3.54) 5.01 (4.89–5.12) −31.1 (−33.5, −28.8) 
Duration of 
Hospitalization 
(days) 
Unknown 10 4.65 (4.50–4.80) 6.43 (6.25–6.61) −27.7 (−30.8, −24.6) 
Rotavirus 2 4.15 (3.79–4.51) 6.1 (5.66–6.54) −32.0 (−39.6, −24.3) 
Duration of  
Fever (days) 
Unknown 13 1.90 (1.80–1.99) 2.81 (2.70–2.92) −32.4 (−36.5, −28.2) 
Rotavirus 4 1.96 (1.78–2.14) 3.18 (2.95–3.41) −38.4 (−45.6, −31.2) 
Duration of  
Vomiting (days) 
Unknown 6 1.15 (1.05–1.25) 1.53 (1.41–1.64) −24.8 (−33.3, −16.4) 
Rotavirus 3 1.84 (1.64–2.04) 2.49 (2.26–2.72) −26.1 (−36.6, −15.6) 
Stool Output (mL) 
Unknown 1 40 (38.1–41.9) 70 (68.0–72.0) −42.9 (−46.0, −39.7) 
Rotavirus 1 278.4 (256.8–300.0) 425.4 (382.1–468.7) −34.6 (−42.9, −26.2) 
Stool Frequency 
(Number per day) 
Unknown 1 4 (3.8–4.2) 8 (7.6–8.4) −50.0 (−53.5, −46.5) 
Rotavirus 2 3.74 (3.30–4.18) 4.27 (3.77–4.77) −12.4 (−27.0, 2.1) 
1 Individual studies may contribute more than one study site (N) to each estimate; 2 Estimates for ≥2 study sites generated 
by Poisson regression model weighted by sample size; 3 Percent difference calculated by: 100 × ((Pooled Zinc  
Estimate − Pooled Control Estimate)/Pooled Control Estimate); 95% CI calculated by: Percent Difference ± 1.96 × 
{|(meanzinc/meancontrol)| × sqrt[(std errorzinc)2/(meanzinc)2 + (std errorcontrol)2/(meancontrol)2]} × 100. 
Table 5. Pooled relative risk of select outcomes for Chinese studies. 
Outcome 
Specific 
Causative 
Pathogens 
Study 
Sites 1 
Pooled Estimate Percentage  
(95% CI) 2 
Relative Risk 3 
N Zinc Group Control Group RR (95% CI) 
Episodes > 3 
days (%) 
Unknown 44 31.4 (29.4–33.5) 49.2 (46.6–51.8) 0.73 (0.66–0.79) 
Rotavirus 29 31.8 (29.5–34.1)  50.3 (47.4–53.3) 0.70 (0.63–0.78) 
Episodes > 7 
days (%) 
Unknown 1 26.9 (-) 39.2 (-) 0.75 (0.42–1.37) 
1 Individual studies may contribute more than one study site (N) to each estimate; 2 Estimates for ≥2 study sites 
generated by Poisson regression model weighted by sample size; 3 Estimates for ≥2 studies generated by 
random effects meta-analysis. 
We did not identify any studies reporting diarrhea-specific or all-cause mortality for inclusion in this 
review. Nor did we identify non-Chinese studies reporting duration of fever or vomiting, or Chinese 
studies reporting the proportion of children vomiting. 
The mean episode duration and proportion of episodes lasting >3 days were not statistically 
significantly different comparing zinc-treated children in Chinese and non-Chinese studies. There was 
no statistically significant difference between the estimated relative risk of an episode lasting >3 days 
(RRR: 1.07; 95% CI: 0.90–1.27) comparing Chinese and non-Chinese studies; therefore, we pooled this 
outcome across regions (RR: 0.74; 95% CI: 0.68–0.80) (Figure 3). The percentage difference between 
the mean episode duration of zinc-treated and control group children was statistically significantly larger 
for Chinese compared to non-Chinese studies (p < 0.05), so this outcome was not pooled across regions. 
We did not have sufficient power to compare other commonly reported outcomes by region. 
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Figure 2. Forest plot for the effect of therapeutic zinc supplementation on Rotavirus diarrhea 
episodes >3 days. 
 
Zinc dose was not associated with the mean percent difference in diarrhea duration comparing zinc 
and control children for non-Chinese (p = 0.50) or Chinese (p = 0.12) studies. Comparing Chinese 
studies that used Licorzinc to those that used other zinc supplements, there were no statistically 
significant differences in the mean percent difference in the duration of rotavirus episodes (p = 0.56), the 
RR of non-specific episodes lasting >3 days (RRR: 0.99; 95% CI: 0.72–1.35), or the RR of rotavirus 
episodes lasting >3 days (RRR: 0.93; 95% CI: 0.68–1.26). The percentage difference in the mean 
duration of non-specific episodes comparing zinc and control group children was statistically 
significantly higher for Licorzinc compared to “other zinc” studies (p = 0.01). 
Our assessment of publication bias yielded largely symmetrical funnel plots for all outcomes. 
Under the CHERG grading system, the studies included in this review were of moderate quality 
(Table 6) [11]. Effect estimates were largely consistent in directionality for all outcomes. 
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Figure 3. Forest plot for the effect of therapeutic zinc supplementation on non-specific 
diarrhea episodes lasting >3 days. 
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Table 6. Quality assessment of studies measuring the association between therapeutic zinc supplementation and selected outcomes. 
Number of 
Studies 
Design Limitations Consistency 
Directness 
Generalizability to 
Population of Interest 
Generalizability to 
Intervention of Interest 
Diarrhea Duration (mean): Moderate outcome-specific quality 1 
53 non-specific 
24 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All but 4 studies showing decreased mean 
duration of diarrhea among zinc-treated 
children (+1) 
Mostly South Asia and 
China (−0.5) Generalizable 
Diarrhea Duration (>3 days): Moderate outcome-specific quality 1 
47 non-specific 
29 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All studies showing decreased risk of 
diarrhea duration >3 days among  
zinc-treated children (+1) 
Mostly South Asia and 
China (−0.5) Generalizable 
Diarrhea Duration (>7 days): Moderate outcome-specific quality 1 
7 non-specific RCT 
Chinese studies not 
placebo-controlled (−0.5)
All but one study showing decreased risk 
of diarrhea duration >7 days among  
zinc-treated children (+1) 
Mostly South Asia and 
China (−0.5) Generalizable 
Hospitalizations Duration: Moderate outcome-specific quality 1 
11 non-specific 
2 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All studies showing decreased mean 
duration of hospitalization among  
zinc-treated children (+1) 
Only one non-Chinese  
study (−0.5) Generalizable 
Stool Output: Moderate outcome-specific quality 1 
3 non-specific 
1 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All but one study showing decreased stool 
output among zinc-treated children (+1) 
Only South Asia and  
China (−0.5) Generalizable 
Stool Frequency: Moderate outcome-specific quality 1 
7 non-specific 
2 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All but three studies showing decreased 
stool frequency among zinc-treated 
children (+1) 
Mostly South Asia and 
China (−0.5) Generalizable 
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Table 6. Cont. 
Vomiting: Moderate outcome-specific quality 1 
3 non-specific RCT None 
All studies showing increased vomiting 
among zinc-treated children (+1) 
No Chinese studies (−0.5) Generalizable 
Vomiting Duration: Moderate outcome-specific quality 1 
6 non-specific 
3 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All but one study showing decreased 
duration of vomiting among zinc-treated 
children (+1) 
No non-Chinese  
studies (−0.5) Generalizable 
Fever Duration: Moderate outcome-specific quality 1 
13 non-specific 
4 Rotavirus 
RCT 
Chinese studies not 
placebo-controlled (−0.5)
All studies showing decreased duration of 
fever among zinc-treated children (+1) 
No non-Chinese  
studies (−0.5) Generalizable 
1 Quality assessment scoring based on previously published criteria [11]. 
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4. Discussion 
The findings of our systematic review confirm and highlight the benefits of therapeutic zinc 
supplementation for diarrhea among children under five years of age in low- and middle-income 
countries. The effects of zinc treatment, which include reductions in episode duration, stool output, stool 
frequency and length of hospitalization, were consistent across Chinese and non-Chinese studies and 
non-specific and rotavirus diarrhea. These results suggest that zinc therapy of diarrhea is largely 
beneficial and important in both low- and middle-income settings. 
The results of the large number of Chinese trials in rotavirus diarrhea are a substantial addition to  
the global evidence base because there have been no non-Chinese trials. One study in India based on a 
post-hoc subgroup analysis suggested that zinc treatment was not beneficial for rotavirus diarrhea [113]; 
however, the evidence from China demonstrates that therapeutic zinc supplementation reduces the 
duration and severity of rotavirus episodes. As rotavirus is the predominant cause of severe acute 
diarrhea worldwide and most likely the leading cause of diarrhea mortality [114], zinc treatment of 
rotavirus diarrhea could potentially yield large reductions in hospitalizations and deaths. 
In comparison to non-Chinese studies, the difference between the mean episode duration of 
zinc-treated and control group children was statistically significantly higher for Chinese studies  
(p < 0.05). It is possible that this difference resulted from lack of placebo-controlled groups and blinding 
among Chinese studies. However, estimates of the effects of therapeutic zinc supplementation on other 
outcomes were largely consistent across study locations and we were able to generate a pooled global 
effect size for the proportion of episodes >3days. The consistency of effect estimates between studies 
conducted in and outside China suggests that the lack of placebo-controlled groups in Chinese studies 
did not greatly bias the results. 
Zinc dose did not affect the estimate of the effect of zinc supplementation on the duration of diarrhea 
for non-Chinese or Chinese studies. Although Licorzinc was associated with slightly greater reductions 
in the mean duration of non-specific diarrhea than other zinc products, zinc effect sizes were generally 
comparable across Chinese studies regardless of type of zinc preparation. 
There is a dearth of literature meeting our inclusion criteria that assessed diarrhea-specific and 
all-cause mortality. Although a previous review published mortality effect estimates [4], the sole study 
reporting diarrhea-specific deaths was cluster-randomized and thus violated our inclusion criteria [115]. 
In addition, three studies of all-cause mortality were also excluded from our review; one was on 
persistent diarrhea [116], and two others were review papers [3,117]. 
Using previously published scoring criteria, the studies included in our review yielded pooled 
estimates of overall moderate quality [11]. The majority of studies contributing to this review were 
conducted in China and South Asia; however, studies conducted outside Asia were consistent in the 
directionality of effect estimates. The consistency and quality of all outcomes bolsters the evidence in 
support of oral zinc supplementation for the treatment of acute diarrhea among children under five in 
low- and middle-income countries. 
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5. Conclusions 
Oral therapeutic zinc supplementation reduces the morbidity of acute diarrhea among children under 
five in and outside China. Global efforts should be made to support scale-up of the WHO recommended 
regimen of therapeutic zinc in all regions. 
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